Dr. Iasonos has been at MSKCC since early 2005. She has collaborated primarily with investigators studying ovarian cancer and also with investigative teams studying bladder cancer, lymphoma, and health outcomes. Through her collaborations with investigators in gynecology (Departments of Surgery, Medicine and Pathology) she is exploring various biomarkers and assessing relationships to histology, metastasis and clinical outcome. She is also involved in vaccine trials as a second line therapy in ovarian cancer patients, and in identifying valid endpoints for these trials. Her methodological interests focus on model based designs that guide the dose escalation in phase I trials and in the past few years she has focused on the design of early phase trials that involve dose expansion cohorts.
Alexia previously served as a member of the institutional Data Safety Monitoring Committee for Phase I-II trials and is currently a member of Research Council which is the Protocol Review and Monitoring System for the Cancer Center Support Grant that reviews protocols for scientific merit, priority, and progress. She is an Associate Editor for the Journal of Clinical Oncology and Clinical Trials.